Mirum Pharmaceuticals, Inc. (MIRM) stock
MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$93.99+0.66 (+0.71%)
Close on Nov 13, 2026Market cap $6.10BP/E –Yield –
Mirum Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Mirum Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was -134.9%. For fiscal 2025 it was -4.2%, against -26.0% the year before. The highest annual figure on record is -4.2% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4.2% | +21.8 |
| FY2024 | Dec 31, 2024 | -26.0% | +32.6 |
| FY2023 | Dec 31, 2023 | -58.6% | +111.7 |
| FY2022 | Dec 31, 2022 | -170.3% | +735.8 |
| FY2021 | Dec 31, 2021 | -906.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -24.1% | −20.2 |
| Q1 FY2026 | Mar 31, 2026 | -493.8% | −480.2 |
| Q4 FY2025 | Dec 31, 2025 | -3.1% | +21.3 |
| Q3 FY2025 | Sep 30, 2025 | 2.0% | +16.0 |
| Q2 FY2025 | Jun 30, 2025 | -3.9% | +27.2 |
| Q1 FY2025 | Mar 31, 2025 | -13.6% | +24.6 |
| Q4 FY2024 | Dec 31, 2024 | -24.4% | +22.5 |
| Q3 FY2024 | Sep 30, 2024 | -14.0% | +38.7 |
| Q2 FY2024 | Jun 30, 2024 | -31.1% | +91.3 |
| Q1 FY2024 | Mar 31, 2024 | -38.2% | +136.9 |
| Q4 FY2023 | Dec 31, 2023 | -46.8% | +133.0 |
| Q3 FY2023 | Sep 30, 2023 | -52.7% | +201.2 |
| Q4 FY2022 | Dec 31, 2022 | -122.4% | +1329.9 |
| Q3 FY2022 | Sep 30, 2022 | -175.1% | +681.4 |
| Q2 FY2022 | Jun 30, 2022 | -179.8% | +160.2 |
| Q1 FY2022 | Mar 31, 2022 | -253.9% | – |
| Q4 FY2021 | Dec 31, 2021 | -1452.4% | – |
| Q3 FY2021 | Sep 30, 2021 | -856.5% | – |
| Q2 FY2021 | Jun 30, 2021 | -340.0% | – |
See a number that looks wrong?